Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $39.5 million.

  • Kymera Therapeutics' Cash from Financing Activities fell 8425.38% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.3 million, marking a year-over-year decrease of 5259.05%. This contributed to the annual value of $608.9 million for FY2024, which is 1442411.74% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Cash from Financing Activities stood at $39.5 million, which was down 8425.38% from $245.7 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Cash from Financing Activities registered a high of $353.8 million during Q1 2024, and its lowest value of -$206000.0 during Q3 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was $1.9 million (2023), whereas its average is $68.5 million.
  • In the last 5 years, Kymera Therapeutics' Cash from Financing Activities tumbled by 10013.69% in 2023 and then skyrocketed by 12190485.44% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Cash from Financing Activities (Quarter) stood at $2.1 million in 2021, then decreased by 4.92% to $2.0 million in 2022, then fell by 0.97% to $1.9 million in 2023, then soared by 42.97% to $2.8 million in 2024, then soared by 1328.93% to $39.5 million in 2025.
  • Its Cash from Financing Activities stands at $39.5 million for Q3 2025, versus $245.7 million for Q2 2025 and $258000.0 for Q1 2025.